Wai BioLogics signs a joint research contract with Galax for AI-based drug development [Korean]

Author: 최유진 기자 | Source: mdtoday.co.kr | Read the full article

In a significant development in the field of cancer treatment, Y-Biologics has announced a partnership with Galax, an AI-based drug development company. The two organizations have signed a collaborative research agreement focused on creating new cancer therapies using artificial intelligence. This partnership aims to leverage AI technology to enhance the design and development of antibody-based immuno-oncology drugs.

Y-Biologics, established in 2007, has been actively involved in developing various biopharmaceutical candidates, either independently or in collaboration with other companies. The company plans to integrate specific drug candidates identified by Galax's AI platform with its own antibody platform to create next-generation immuno-oncology drugs. This collaboration is expected to accelerate the development of innovative treatments for cancer.

Galax, founded by a research team from Seoul National University, specializes in predicting protein structures and interactions using advanced AI techniques. Their unique drug design platform, known as Galax Design, combines physical chemistry with artificial intelligence to streamline the drug development process. This partnership marks a promising step forward in the quest for effective cancer therapies.

[Read More]